References


  1. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004;31:1582-1587.

  2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038-2047.

  3. Krishnan E, Lienesch D, Kwoh CK. Gout in ambulatory care settings in the United States. J Rheumatol 2008;35:498-501.

  4. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med 2008;75(suppl 5):S13-S16.

  5. Gaffo AL, Saag KG. Management of hyperuricemia and gout in CKD. Am J Kidney Dis 2008;52:994-1009.

  6. Wu CH, Lee CT, Lee CH, et al. Urinary UMOD excretion and chronic kidney disease in gout patients: cross-sectional case-control study. Ren Fail 2011;33:164-168.

  7. Fuldeore MJ, Riedel AA, Zarotsky V, et al. Chronic kidney disease in gout in a managed care setting. BMC Nephrol 2011;12:36.

  8. El-Zawawy H, Mandell BF. Managing gout: how is it different in patients with chronic kidney disease? Cleve Clin J Med 2010;77:919-927.

  9. Primatesta P, Plana E, Rothenbacher D. Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population. BMC Musculoskelet Disord 2011;12:103.

  10. Gibson T. Hyperuricemia, gout and the kidney. Curr Opin Rheumatol 2011 Dec 12. [Epub ahead of print]

  11. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of kidney disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006;47:51-59.

  12. Goicoechea M, García de Vinuesa S, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5:1388-1393.

  13. Krishnan E, Baker JF, Furst DE, Schumacher HR Jr. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688-2696.

  14. Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000;36:1072-1078.

  15. Bos MJ , Koudstaal PJ, Hofman A, et al. Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam Study. Stroke 2006;37:1503-1507.

  16. Reinders MK, Jansen TL. New advances in the treatment of gout: review of pegloticase. Ther Clin Risk Manag 2010;6:543-550.

  17. Silva L, Miguel ED, Peiteado D, et al. Compliance in gout patients. Acta Rheumatol Port 2010;35:466-474.

  18. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician 1999;59(4):925-934.

  19. Zyloprim® (allopurinol) [package insert]. San Diego, CA: Prometheus Laboratories, Inc.; 2009.

  20. Panomvana D, Sripradit S, Angthararak S. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. J Clin Rheumatol 2008;14:6-11.

  21. Gaffo AL, Saag KG. Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. Core Evid 2009;4:25-36.

  22. Uloric (febuxostat) tablet for oral use [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2011.

  23. Krystexxa™ (pegloticase) Injection, for intravenous infusion [package insert]. East Brunswick, NJ: Savient Pharmaceuticals, Inc.; 2010.


From the April 01, 2012 Issue of Renal and Urology News